01/25/23 4:05 PMNasdaq : ARDS clinical triallow floatAridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of careRHEA-AIneutral
01/17/23 4:30 PMNasdaq : ARDS clinical triallow floatNew Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial UpdateAridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused onRHEA-AIneutral
12/28/22 8:30 AMNasdaq : ARDS clinical triallow floatAridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, will host a conference call and audio-only webcast onRHEA-AIneutral
12/12/22 8:05 AMNasdaq : ARDS low float(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis FoundationAridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development ofRHEA-AIvery positive
12/12/22 7:00 AMNasdaq : ARDS low floatAridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis FoundationAridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company today announced the Cystic Fibrosis Foundation invested $4.85 million in Aridis common stock on market terms under NASDAQ rules to support the ongoing development ofRHEA-AIvery positive
12/05/22 7:00 AMNasdaq : ARDS low floatAridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp BiopharmaceuticalAridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , aRHEA-AIpositive
11/30/22 7:00 AMNasdaq : ARDS clinical triallow floatAridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis PatientsAridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today announced the closing of patient enrollment inRHEA-AIvery positive
11/22/22 9:10 AMNasdaq : ARDS conferenceslow floatAridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious DiseasesAridis Pharmaceuticals, Inc. (NASDAQ: ARDS) , a biopharmaceutical companyRHEA-AIneutral
10/04/22 8:00 AMNasdaq : ARDS clinical triallow floatAridis Announces the Closing of Patient Enrollment in the AR-301 Global Phase 3 Superiority StudyAridis Pharmaceuticals, Inc. (NASDAQ: ARDS) announced today that patient enrollment is closed in the AR-301 Phase 3 clinical study. TheRHEA-AIneutral
09/27/22 9:20 AMNasdaq : ARDS offeringlow floatAridis Pharmaceuticals Announces Withdrawal of Public Offering of Common StockAridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today announced that due to adverse market conditions, it hasRHEA-AIneutral